Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel dose and verapamil interaction study in elective PCI for coronary artery disease
ACTRN12606000129583Phase 4Not yet recruiting
- Sponsor
- Auckland City Hospital
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of clopidogrel and verapamil in coronary arteriosclerosis (4 arms), sponsored by Auckland City Hospital. Primary endpoints: Platelet function by VerifyNow P2Y12 analyzer and Peak troponin and creatine kinase. Planned start May 2006; status: not yet recruiting.
02
Drugs
clopidogrelverapamil
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12606000129583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000129583.